| Unresectable/metastic 2nd line |
| Study Number: |
MEL 19 SCRI |
| Protocol title: |
A Phase II Study of Everolimus in Combination with Paclitaxel and Carboplatin in Patients with Metastatic Melanoma |
| Status: |
Open |
|
| Study Number: |
MEL 20 H8K-MC-JZAO Eli Lilly & Company |
| Protocol title: |
A Randomized Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-line Treatment in patients with Unresectable or Metastatic Melanoma |
| Status: |
Open |